FGF2 and major depressive disorder: Whether astroglia, astroglial functions, or HPA changes are the downstream target of FGF2 mediated changes induced by fluoxetine remains to be determined, however, the current study reaffirms the potential of FGF2 as a novel therapeutic target in the treatment of depression and anxiety disorders.